应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02005 石四药集团
交易中 04-26 13:27:18
4.770
+0.030
+0.63%
最高
4.820
最低
4.720
成交量
98.00万
今开
4.770
昨收
4.740
日振幅
2.11%
总市值
141.62亿
流通市值
141.62亿
总股本
29.69亿
成交额
466.71万
换手率
0.03%
流通股本
29.69亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
石四药集团利奈唑胺干混悬剂获批上市 为国内首仿
新京报 · 04-23 14:44
石四药集团利奈唑胺干混悬剂获批上市 为国内首仿
石四药集团:利奈唑胺干混悬剂获药监局批件
和讯网 · 04-23
石四药集团:利奈唑胺干混悬剂获药监局批件
石四药集团(02005)已取得利奈唑胺干混悬剂(5ml:100mg)的药品生产注册批件
智通财经 · 04-23
石四药集团(02005)已取得利奈唑胺干混悬剂(5ml:100mg)的药品生产注册批件
石四药集团(02005.HK)利奈唑胺干混悬剂获国家药监局生产注册批件
阿斯达克财经 · 04-23
石四药集团(02005.HK)利奈唑胺干混悬剂获国家药监局生产注册批件
石四药集团(02005.HK)获执行董事曲继广增持100万股
格隆汇资讯 · 04-19
石四药集团(02005.HK)获执行董事曲继广增持100万股
石四药集团(02005.HK):业绩符合预期 净利润率同比提升
中金公司 · 04-18
石四药集团(02005.HK):业绩符合预期 净利润率同比提升
石四药集团执行董事曲继广增持80万股,持股比例升至37.61%
和讯网 · 04-18
石四药集团执行董事曲继广增持80万股,持股比例升至37.61%
石四药集团(02005.HK)获执行董事曲继广增持80万股
港股那点事 · 04-18
石四药集团(02005.HK)获执行董事曲继广增持80万股
石四药集团盘中异动 下午盘股价大涨5.22%
自选股智能写手 · 04-17
石四药集团盘中异动 下午盘股价大涨5.22%
石四药集团(02005)股价上升5.217%,现价港币$4.84
阿斯达克财经 · 04-17
石四药集团(02005)股价上升5.217%,现价港币$4.84
石四药集团现涨超3% 一季度股东应占溢利同比增长约14.6%
新浪港股 · 04-17
石四药集团现涨超3% 一季度股东应占溢利同比增长约14.6%
维达国际被移出港股通 石四药集团一季度溢利增长14.6%
和讯 · 04-17
维达国际被移出港股通 石四药集团一季度溢利增长14.6%
港股异动 | 石四药集团(02005)涨近4% 一季度股东应占溢利同比增长约14.6%
智通财经 · 04-17
港股异动 | 石四药集团(02005)涨近4% 一季度股东应占溢利同比增长约14.6%
石四药涨超4%,Q1股东应占溢利同比增14.6%
金融界 · 04-17
石四药涨超4%,Q1股东应占溢利同比增14.6%
【港股通】石四药集团(02005)涨近3% 首季溢利同比增加约14.6%至约4.16亿港元
金吾财讯 · 04-17
【港股通】石四药集团(02005)涨近3% 首季溢利同比增加约14.6%至约4.16亿港元
智通港股早知道 | 国家药监局:加快推动医疗机器人标志性产品上市应用 港交所:主动型ETF成为香港市场新宠
智通财经 · 04-17
智通港股早知道 | 国家药监局:加快推动医疗机器人标志性产品上市应用 港交所:主动型ETF成为香港市场新宠
音频 | 格隆汇4.17盘前要点—港A美股你需要关注的大事都在这
格隆汇 · 04-17
音频 | 格隆汇4.17盘前要点—港A美股你需要关注的大事都在这
石四药集团净利润上升14.6% 营业额增2.9%至17.99亿港元
和讯网 · 04-16
石四药集团净利润上升14.6% 营业额增2.9%至17.99亿港元
【港股通】石四药集团(02005)首季溢利增长约14.6%至约4.16亿港元
金吾财讯 · 04-16
【港股通】石四药集团(02005)首季溢利增长约14.6%至约4.16亿港元
石四药集团(02005)第一季度股东应占溢利约4.16亿港元 同比增长约14.6%
智通财经 · 04-16
石四药集团(02005)第一季度股东应占溢利约4.16亿港元 同比增长约14.6%
加载更多
公司概况
公司名称:
石四药集团
所属市场:
SEHK
上市日期:
--
主营业务:
石四药集团有限公司,前称为利君国际医药(控股)有限公司,是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药,包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。
发行价格:
--
{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":4.77,"timestamp":1714108899309,"preClose":4.74,"halted":0,"volume":980000,"delay":0,"floatShares":2969043385,"shares":2969043385,"eps":0.44407,"marketStatus":"交易中","marketStatusCode":2,"change":0.03,"latestTime":"04-26 13:27:18","open":4.77,"high":4.82,"low":4.72,"amount":4667080,"amplitude":0.021097,"askPrice":4.78,"askSize":38000,"bidPrice":4.77,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":0.442599,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714119000000},"adr":0,"listingDate":1135008000000,"adjPreClose":4.74,"dividendRate":0.035639,"openAndCloseTimeList":[[1714095000000,1714104000000],[1714107600000,1714118400000]],"volumeRatio":0.803633,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2429715674","title":"石四药集团利奈唑胺干混悬剂获批上市 为国内首仿","url":"https://stock-news.laohu8.com/highlight/detail?id=2429715674","media":"新京报","top":-1,"share":"https://www.laohu8.com/m/news/2429715674?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:44","pubTimestamp":1713854672,"startTime":"0","endTime":"0","summary":"石四药集团是国内首家获批企业,此前,石四药集团已获得利奈唑胺的原料药及注射剂的生产批件。目前,国内市场上的利奈唑胺制剂有葡萄糖注射液、片剂和干混悬剂,其中干混悬剂除本次获批的石四药集团,仅有辉瑞的原研药获批进口,此外,浙江普利药业已提交利奈唑胺干混悬剂的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042314454187a4c244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042314454187a4c244&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429615863","title":"石四药集团:利奈唑胺干混悬剂获药监局批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2429615863","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429615863?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:20","pubTimestamp":1713849615,"startTime":"0","endTime":"0","summary":"【石四药集团获得利奈唑胺干混悬剂生产批件】 石四药集团今日公告,已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类,标志着公司通过了一致性评价。公告中指出,利奈唑胺干混悬剂为口服混悬剂型,石四药集团成为国内首家获此殊荣的企业。此前,该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者,主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、社区获得性肺炎、皮肤和皮肤软组织感染,以及万古霉素耐药的屎肠球菌感染。此次批件的获得,预计将为该集团带来新的市场机遇和盈利增长点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429131279","title":"石四药集团(02005)已取得利奈唑胺干混悬剂(5ml:100mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2429131279","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429131279?lang=zh_cn&edition=full","pubTime":"2024-04-23 12:06","pubTimestamp":1713845216,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石四药集团(02005)发布公告,集团已取得中国国家药品监督管理局有关利奈唑胺干混悬剂(5ml:100mg)的药品生产注册批件,属于化学药品第4类,视同通过一致性评价。公告称,利奈唑胺干混悬剂属口服混悬剂型,集团是国内企业首家获批,之前已获得利奈唑胺的原料药及注射剂的生产批件。利奈唑胺干混悬剂可用于新生儿、儿童及成年患者,主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、社区获得性肺炎、皮肤和皮肤软组织感染以及万古霉素耐药的屎肠球菌感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107376.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429348071","title":"石四药集团(02005.HK)利奈唑胺干混悬剂获国家药监局生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2429348071","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429348071?lang=zh_cn&edition=full","pubTime":"2024-04-23 12:06","pubTimestamp":1713845160,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK) 公布,已取得中国国家药品监督管理局有关利奈唑胺干混悬剂(5ml : 100mg)的药品生产注册批件,属于化学药品第4类,视同通过一致性评价。利奈唑胺干混悬剂属口服混悬剂型,公司是国内企业首家获批,之前已获得利奈唑胺的原料药及注射剂的生产批件。利奈唑胺干混悬剂可用于新生儿、儿童及成年患者,主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、社区获得性肺炎、皮肤和皮肤软组织感染以及万古霉素耐药的屎肠球菌感染。(cy/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220419120905434_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220419120905434_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344258/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428529515","title":"石四药集团(02005.HK)获执行董事曲继广增持100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428529515","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2428529515?lang=zh_cn&edition=full","pubTime":"2024-04-19 06:48","pubTimestamp":1713480495,"startTime":"0","endTime":"0","summary":"格隆汇4月19日丨根据联交所最新权益披露资料显示,2024年4月18日,石四药集团(02005.HK)获执行董事曲继广在场内以每股均价4.6752港元增持100万股,涉资约467.52万港元。增持后,曲继广最新持股数目为1,117,706,000股,持股比例由37.61%上升至37.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190648218b37c074&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190648218b37c074&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428560238","title":"石四药集团(02005.HK):业绩符合预期 净利润率同比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2428560238","media":"中金公司","top":-1,"share":"https://www.laohu8.com/m/news/2428560238?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:51","pubTimestamp":1713441104,"startTime":"0","endTime":"0","summary":"发展趋势2024 年1 季度,静脉输液销售额收入同比增长1.3%至10.65 亿港元。净利润率同比提升。2024 年1 季度,公司综合毛利率为57.3%,同比下降0.3 个百分点;公司综合净利率为23.1%,同比增加2.4 个百分点,主要由于费用率进一步优化。盈利预测与估值我们维持2024/2025 年收入及净利润预测不变。风险新产品销量下降,集采结果低于预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181951458b35ec21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181951458b35ec21&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428581858","title":"石四药集团执行董事曲继广增持80万股,持股比例升至37.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428581858","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2428581858?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:56","pubTimestamp":1713405393,"startTime":"0","endTime":"0","summary":"4月18日, 石四药集团 宣布,公司执行董事曲继广在4月17日于联交所场内以每股均价4.763港元增持80万股,涉资约381.04万港元。增持后,曲继广的最新持股数目增至1,116,706,000股,持股比例从37.58%上升至37.61%。此次增持行为可能对石四药集团的股价产生积极影响,显示出公司管理层对公司未来发展的信心。对于二级市场投资者而言,石四药集团的此次增持行为可能会引起关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181030218b32a0ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181030218b32a0ea&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428068773","title":"石四药集团(02005.HK)获执行董事曲继广增持80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428068773","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2428068773?lang=zh_cn&edition=full","pubTime":"2024-04-18 07:50","pubTimestamp":1713397803,"startTime":"0","endTime":"0","summary":"格隆汇4月18日丨根据联交所最新权益披露资料显示,2024年4月17日,石四药集团(02005.HK)获执行董事曲继广在场内以每股均价4.763港元增持80万股,涉资约381.04万港元。增持后,曲继广最新持股数目为1,116,706,000股,持股比例由37.58%上升至37.61%。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inaseyrh7922952.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inaseyrh7922952.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428946365","title":"石四药集团盘中异动 下午盘股价大涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428946365","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428946365?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:00","pubTimestamp":1713333622,"startTime":"0","endTime":"0","summary":"2024年04月17日下午盘14时00分,石四药集团股票出现波动,股价快速上涨5.22%。石四药集团股票所在的药品行业中,整体跌幅为0.09%。消息层面,截至14时00分,《石四药集团净利润上升14.6% 营业额增2.9%至17.99亿港元》资讯为影响石四药集团的重要信息。该信息摘要如下:石四药集团一季度净利润增长14.6%。石四药集团2024年第一季度未经审核财报显示,公司营业额同比增长2.9%,达到17.99亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417140022861e69cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417140022861e69cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428656223","title":"石四药集团(02005)股价上升5.217%,现价港币$4.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2428656223","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428656223?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:00","pubTimestamp":1713333600,"startTime":"0","endTime":"0","summary":"[上升股]石四药集团(02005) 股价在下午02:00比前收市价上升5.217%,现股价为港币$4.84。至目前为止,今日最高价为$4.84,而最低价为$4.63。总成交量为175.6万股,总成交金额为港币$834.392万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240417910/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428135860","title":"石四药集团现涨超3% 一季度股东应占溢利同比增长约14.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428135860","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2428135860?lang=zh_cn&edition=full","pubTime":"2024-04-17 10:43","pubTimestamp":1713321780,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 石四药集团(02005)早盘上涨3.04%,现报4.74港元,成交额429.23万港元。\n 石四药集团公布,截至2024年3月31日止3个月,集团未经审核公司股东应占溢利同比增加约14.6%至约4.16亿港元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-17/doc-inasazxy9678775.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-17/doc-inasazxy9678775.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428332910","title":"维达国际被移出港股通 石四药集团一季度溢利增长14.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428332910","media":"和讯","top":-1,"share":"https://www.laohu8.com/m/news/2428332910?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:58","pubTimestamp":1713319081,"startTime":"0","endTime":"0","summary":"快讯正文每日港股市场要闻速递深交所宣布,调整深港通下港股通标的证券名单,维达国际被移出。石四药集团披露,一季度股东应占溢利约4.16亿港元,同比增长约14.6%。新华保险数据显示,前3月原保险保费收入累计571.93亿元,同比下降11.7%。中国电力公告,前3月总售电量达2997.01万兆瓦时,同比增加31.99%。中煤能源公布,前3月商品煤产量为3273万吨,同比减少1.7%,商品煤销量6387万吨,同比减少14.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170959248786a510&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170959248786a510&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428334024","title":"港股异动 | 石四药集团(02005)涨近4% 一季度股东应占溢利同比增长约14.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428334024","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428334024?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:54","pubTimestamp":1713318871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,石四药集团(02005)涨近4%,截至发稿,涨3.91%,报4.78港元,成交额283.83万港元。消息面上,石四药集团公布,截至2024年3月31日止3个月,集团未经审核公司股东应占溢利同比增加约14.6%至约4.16亿港元。公告称,集团销售主要在中国进行,并以人民币计值,期内人民币兑港元较2023年同期贬值约3.6%。因此,按港元计,未经审核营业额较2023年同期仅增加2.9%至约17.99亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103685.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428334959","title":"石四药涨超4%,Q1股东应占溢利同比增14.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428334959","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428334959?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:47","pubTimestamp":1713318450,"startTime":"0","endTime":"0","summary":"石四药集团(2005.HK)盘初拉升涨超4%报4.8港元,市值143亿港元。石四药昨晚公布首季业绩,未经审核股东应占溢利同比增加约14.6%至约4.2亿港元。公司表示,集团销售主要在中国进行,并以人民币计值,期内人民币兑港元同比贬值约3.6%,因此未经审核营业额同比仅增加2.9%至约18亿港元。毛利增加2.3%至约10.3亿港元,毛利率约为57.3%,较去年同期轻微下降0.3个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709520787869d41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709520787869d41&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428270331","title":"【港股通】石四药集团(02005)涨近3% 首季溢利同比增加约14.6%至约4.16亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428270331","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2428270331?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:43","pubTimestamp":1713318216,"startTime":"0","endTime":"0","summary":"金吾财讯 | 石四药集团(02005)首季初步业绩向好,带动盘初股价上扬,截止发稿,涨2.83%,报4.73港元,成交额156.2万港元。公司日前公布,截至3月31日止3个月,未经审核公司股东应占溢利同比增加约14.6%至约4.16亿港元。期内,集团未经审核营业额同比增加2.9%至约17.99亿港元;毛利增加2.3%至约10.31亿港元;毛利率约为57.3%,同比下跌0.3个百分点。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ODEyMDM1NzM2NTU5NjM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODEyMDM1NzM2NTU5NjM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935196","is_publish_highlight":false,"gpt_icon":0},{"id":"2428380831","title":"智通港股早知道 | 国家药监局:加快推动医疗机器人标志性产品上市应用 港交所:主动型ETF成为香港市场新宠","url":"https://stock-news.laohu8.com/highlight/detail?id=2428380831","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428380831?lang=zh_cn&edition=full","pubTime":"2024-04-17 07:50","pubTimestamp":1713311421,"startTime":"0","endTime":"0","summary":"国家药监局:研究出台针对性举措 加快推动医疗机器人标志性产品上市应用4月16日,医疗机器人创新发展座谈会在北京昌平召开。国家药监局党组成员、副局长徐景和出席。国家药监局将进一步强化部委间合作,推动产学医研管协同发力,研究出台针对性举措,加快推动标志性产品上市应用,以科学监管促进医疗机器人创新高质量发展,更好满足公众健康需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103644.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428875133","title":"音频 | 格隆汇4.17盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2428875133","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2428875133?lang=zh_cn&edition=full","pubTime":"2024-04-17 07:40","pubTimestamp":1713310830,"startTime":"0","endTime":"0","summary":"美股三大指数收盘涨跌互现,特斯拉市值跌至不足5000亿美元;中国一季度重磅数据出炉,GDP增速超市场预期;误伤小盘股!证监会深夜回应;三部门指扩大战略性新兴产业信用贷款规模;月内第三家!又一券商被立案;医保局称司美格鲁肽不是用来“减肥”的...","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/109.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/720070","is_publish_highlight":false,"gpt_icon":0},{"id":"2427884410","title":"石四药集团净利润上升14.6% 营业额增2.9%至17.99亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427884410","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2427884410?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:34","pubTimestamp":1713260040,"startTime":"0","endTime":"0","summary":"快讯正文石四药集团一季度净利润增长14.6%石四药集团2024年第一季度未经审核财报显示,公司营业额同比增长2.9%,达到17.99亿港元。股东应占溢利实现约4.16亿港元,去年同期为3.63亿港元,呈现14.6%的增长。和讯自选股写手风险提示:以上内容仅作为作者或者嘉宾的观点,不代表和讯的任何立场,不构成与和讯相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性,对此和讯不做任何保证和承诺。下载和讯APP查看快讯,体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161807078783bf45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161807078783bf45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427106888","title":"【港股通】石四药集团(02005)首季溢利增长约14.6%至约4.16亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427106888","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2427106888?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:46","pubTimestamp":1713257172,"startTime":"0","endTime":"0","summary":"金吾财讯 | 石四药集团(02005)公布,截至3月31日止3个月,未经审核公司股东应占溢利同比增加约14.6%至约4.16亿港元。期内,集团未经审核营业额同比增加2.9%至约17.99亿港元;毛利增加2.3%至约10.31亿港元;毛利率约为57.3%,同比下跌0.3个百分点。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/ODE4NTE0MmIxODUzZmU5MzU2YjViMWM2ZTMxMDAwMDkzMzkyMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/ODE4NTE0MmIxODUzZmU5MzU2YjViMWM2ZTMxMDAwMDkzMzkyMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935163","is_publish_highlight":false,"gpt_icon":0},{"id":"2427817419","title":"石四药集团(02005)第一季度股东应占溢利约4.16亿港元 同比增长约14.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427817419","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427817419?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:35","pubTimestamp":1713256533,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石四药集团 发布公告,该集团销售主要在中国进行,并以人民币计值,截至2024年3月31日止3个月,人民币兑港元较2023年同期贬值约3.6%。截至2024年3月31日止3个月,集团未经审核公司股东应占溢利较2023年同期增加约14.6%至约4.16亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103266.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0557},{"period":"3month","weight":0.0557},{"period":"6month","weight":0.1179},{"period":"1year","weight":-0.1114},{"period":"ytd","weight":-0.0405}],"compareEarnings":[{"period":"1week","weight":0.0548},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0835},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1252},{"period":"ytd","weight":0.0139}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药(控股)有限公司,是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药,包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.526316,"avgChangeRate":0.012746},{"month":2,"riseRate":0.578947,"avgChangeRate":0.027337},{"month":3,"riseRate":0.684211,"avgChangeRate":0.091025},{"month":4,"riseRate":0.526316,"avgChangeRate":0.041938},{"month":5,"riseRate":0.444444,"avgChangeRate":0.010087},{"month":6,"riseRate":0.555556,"avgChangeRate":0.084151},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.03341},{"month":8,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.061971},{"month":10,"riseRate":0.444444,"avgChangeRate":0.001133},{"month":11,"riseRate":0.722222,"avgChangeRate":0.099601},{"month":12,"riseRate":0.5,"avgChangeRate":-0.005875}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}